+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neuroprotection Market by Indication, Product Type, Mechanism of Action, Distribution Channel, End User - Global Forecast to 2030- Product Image
Neuroprotection Market by Indication, Product Type, Mechanism of Action, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Neuroprotection Market by Indication, Product Type, Mechanism of Action, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4857892
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The neuroprotection market is positioned for sustained growth, driven by demographic trends and advances in therapeutic innovation. As the clinical and regulatory landscapes continue to evolve, business leaders must navigate emerging opportunities and risks with agility and strategic insight.

Market Snapshot: Neuroprotection Market Size and Growth

The Neuroprotection Market grew from USD 311.79 billion in 2024 to USD 336.31 billion in 2025. It is expected to continue growing at a CAGR of 7.72%, reaching USD 487.27 billion by 2030.

Scope & Segmentation Overview

  • Indication: Alzheimer’s disease (early, moderate, severe stages), multiple sclerosis (relapsing remitting, secondary progressive forms), Parkinson’s disease (postural instability, tremor-dominant), spinal cord injury, stroke (hemorrhagic, ischemic), traumatic brain injury.
  • Product Type: Biologics (monoclonal antibodies, neurotrophic factor therapies), peptide and small molecule drugs, gene therapy, nutraceuticals (herbal extracts, vitamins, minerals), stem cell therapy.
  • Mechanism of Action: Anti-inflammatory agents (cytokine inhibitors, NSAIDs, steroids), antioxidants (flavonoids, vitamin C, vitamin E), calcium channel blockers (flunarizine, nimodipine), glutamate inhibitors, neurotrophic factors, NMDA antagonists (ketamine, memantine).
  • Distribution Channel: E-commerce (direct manufacturer, third-party), hospital pharmacies, online pharmacies (international, local), retail pharmacies (chain, independent).
  • End User: Clinics (outpatient, specialty), home healthcare (provider services, self-medication), hospitals (private, public), research institutes (academic, government).
  • Regions Covered: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, and others), Asia-Pacific (including China, India, Japan, Australia, South Korea, Southeast Asia nations).
  • Leading Companies: Novartis AG, Roche Holding AG, Biogen Inc., Pfizer Inc., AbbVie Inc., Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc., AstraZeneca PLC, GlaxoSmithKline plc.

Key Takeaways for Strategic Decision-Making

  • Rising prevalence of neurodegenerative conditions increases demand for novel neuroprotective therapies, creating space for differentiated products across multiple disease areas.
  • Converging advances in gene therapy, biologics, and stem cell approaches are expanding the addressable market and changing standard treatment algorithms.
  • Digital health technologies such as AI-enabled drug discovery and remote patient monitoring are accelerating innovation and shaping new clinical endpoints.
  • Strategic partnerships between pharmaceutical companies, biotech firms, and research institutions enhance R&D capabilities and dilute risk, speeding development and commercialization timelines.
  • Region-specific factors, including robust reimbursement in North America and emerging research hubs in Asia-Pacific, are reshaping competitive dynamics and market access strategies.
  • Segmented distribution, especially growth in e-commerce and specialized clinic channels, is redefining purchasing behaviors among end-users.

Tariff Impact on the Neuroprotection Market

New US tariffs imposed in 2025 have led to increased manufacturing costs for companies dependent on imported pharmaceutical ingredients and biomedical equipment. This has fostered investment in domestic supply and motivated firms to reassess supplier networks. Some companies have realized cost efficiencies through vertical integration, while others have diversified manufacturing hubs or renegotiated supplier agreements. The resulting focus on localization and regional supply chains has bolstered ecosystem resilience and encouraged new partnerships, particularly among contract manufacturing organizations and innovative biotech companies.

Methodology & Data Sources

This analysis leverages a mixed-method approach, blending secondary research from clinical literature, regulatory filings, trial registries, and patent data with primary insights from interviews with industry leaders and operational executives. Data consistency is ensured through triangulation and validation by expert panels.

Why This Report Matters

  • Enables leaders to respond quickly to evolving therapy trends, competitive activity, and regulatory developments within the neuroprotection market.
  • Supports data-driven investment, R&D prioritization, and partnership strategies by providing a comprehensive segmentation view and actionable market insights.
  • Guides supply chain and market access planning in the context of shifting tariff policies and regional dynamics.

Conclusion

The neuroprotection market reflects a dynamic intersection of scientific advancement, policy evolution, and shifting patient needs. Senior decision-makers equipped with actionable insights will be better positioned to lead and succeed in this complex, opportunity-rich environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Neuroprotection Market, by Indication
8.1. Introduction
8.2. Alzheimer's Disease
8.2.1. Early Stage Alzheimer's Disease
8.2.2. Moderate Stage Alzheimer's Disease
8.2.3. Severe Stage Alzheimer's Disease
8.3. Multiple Sclerosis
8.3.1. Relapsing Remitting Multiple Sclerosis
8.3.2. Secondary Progressive Multiple Sclerosis
8.4. Parkinson's Disease
8.4.1. Postural Instability Parkinson's Disease
8.4.2. Tremor Dominant Parkinson's Disease
8.5. Spinal Cord Injury
8.6. Stroke
8.6.1. Hemorrhagic Stroke
8.6.2. Ischemic Stroke
8.7. Traumatic Brain Injury
9. Neuroprotection Market, by Product Type
9.1. Introduction
9.2. Biologics
9.2.1. Monoclonal Antibody Biologics
9.2.2. Neurotrophic Factor Biologics
9.3. Drugs
9.3.1. Peptide Drugs
9.3.2. Small Molecule Drugs
9.4. Gene Therapy
9.5. Nutraceuticals
9.5.1. Herbal Extract Nutraceuticals
9.5.2. Mineral Nutraceuticals
9.5.3. Vitamin Nutraceuticals
9.6. Stem Cell Therapy
10. Neuroprotection Market, by Mechanism of Action
10.1. Introduction
10.2. Anti Inflammatory Agents
10.2.1. Cytokine Inhibitor Anti Inflammatory Agents
10.2.2. NSAID Anti Inflammatory Agents
10.2.3. Steroid Anti Inflammatory Agents
10.3. Antioxidants
10.3.1. Flavonoid Antioxidants
10.3.2. Vitamin C Antioxidants
10.3.3. Vitamin E Antioxidants
10.4. Calcium Channel Blockers
10.4.1. Flunarizine Calcium Channel Blockers
10.4.2. Nimodipine Calcium Channel Blockers
10.5. Glutamate Inhibitors
10.6. Neurotrophic Factors
10.7. NMDA Antagonists
10.7.1. Ketamine NMDA Antagonists
10.7.2. Memantine NMDA Antagonists
11. Neuroprotection Market, by Distribution Channel
11.1. Introduction
11.2. E Commerce
11.2.1. Direct Manufacturer E Commerce
11.2.2. Third Party E Commerce
11.3. Hospital Pharmacies
11.4. Online Pharmacies
11.4.1. International Online Pharmacies
11.4.2. Local Online Pharmacies
11.5. Retail Pharmacies
11.5.1. Chain Retail Pharmacies
11.5.2. Independent Retail Pharmacies
12. Neuroprotection Market, by End User
12.1. Introduction
12.2. Clinics
12.2.1. Outpatient Clinics
12.2.2. Specialty Clinics
12.3. Home Healthcare
12.3.1. Provider Services Home Healthcare
12.3.2. Self Medication Home Healthcare
12.4. Hospitals
12.4.1. Private Hospitals
12.4.2. Public Hospitals
12.5. Research Institutes
12.5.1. Academic Research Institutes
12.5.2. Government Research Institutes
13. Americas Neuroprotection Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Neuroprotection Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Neuroprotection Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. Roche Holding AG
16.3.3. Biogen Inc.
16.3.4. Pfizer Inc.
16.3.5. AbbVie Inc.
16.3.6. Eli Lilly and Company
16.3.7. Johnson & Johnson
16.3.8. Merck & Co., Inc.
16.3.9. AstraZeneca PLC
16.3.10. GlaxoSmithKline plc
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. NEUROPROTECTION MARKET MULTI-CURRENCY
FIGURE 2. NEUROPROTECTION MARKET MULTI-LANGUAGE
FIGURE 3. NEUROPROTECTION MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. NEUROPROTECTION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. NEUROPROTECTION MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. NEUROPROTECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY EARLY STAGE ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY MODERATE STAGE ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY SEVERE STAGE ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NEUROPROTECTION MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NEUROPROTECTION MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NEUROPROTECTION MARKET SIZE, BY POSTURAL INSTABILITY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREMOR DOMINANT PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NEUROPROTECTION MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NEUROPROTECTION MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NEUROPROTECTION MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NEUROPROTECTION MARKET SIZE, BY MONOCLONAL ANTIBODY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTOR BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NEUROPROTECTION MARKET SIZE, BY PEPTIDE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NEUROPROTECTION MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NEUROPROTECTION MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL NEUROPROTECTION MARKET SIZE, BY HERBAL EXTRACT NUTRACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL NEUROPROTECTION MARKET SIZE, BY MINERAL NUTRACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN NUTRACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL NEUROPROTECTION MARKET SIZE, BY CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL NEUROPROTECTION MARKET SIZE, BY NSAID ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEROID ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLAVONOID ANTIOXIDANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN C ANTIOXIDANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN E ANTIOXIDANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLUNARIZINE CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL NEUROPROTECTION MARKET SIZE, BY NIMODIPINE CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL NEUROPROTECTION MARKET SIZE, BY KETAMINE NMDA ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL NEUROPROTECTION MARKET SIZE, BY MEMANTINE NMDA ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL NEUROPROTECTION MARKET SIZE, BY E COMMERCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL NEUROPROTECTION MARKET SIZE, BY DIRECT MANUFACTURER E COMMERCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL NEUROPROTECTION MARKET SIZE, BY THIRD PARTY E COMMERCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL NEUROPROTECTION MARKET SIZE, BY E COMMERCE, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL NEUROPROTECTION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL NEUROPROTECTION MARKET SIZE, BY INTERNATIONAL ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL NEUROPROTECTION MARKET SIZE, BY LOCAL ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL NEUROPROTECTION MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL NEUROPROTECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL NEUROPROTECTION MARKET SIZE, BY CHAIN RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDEPENDENT RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL NEUROPROTECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL NEUROPROTECTION MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL NEUROPROTECTION MARKET SIZE, BY PROVIDER SERVICES HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL NEUROPROTECTION MARKET SIZE, BY SELF MEDICATION HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL NEUROPROTECTION MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL NEUROPROTECTION MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL NEUROPROTECTION MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS NEUROPROTECTION MARKET SIZE, BY E COMMERCE, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS NEUROPROTECTION MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS NEUROPROTECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS NEUROPROTECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS NEUROPROTECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 116. AMERICAS NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 117. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES NEUROPROTECTION MARKET SIZE, BY E COMMERCE, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES NEUROPROTECTION MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES NEUROPROTECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES NEUROPROTECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES NEUROPROTECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 142. CANADA NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. CANADA NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 144. CANADA NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 145. CANADA NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2030 (USD MILLION)
TABLE 146. CANADA NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
TABLE 147. CANADA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 148. CANADA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 149. CANADA NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 150. CANADA NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 151. CANADA NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 152. CANADA NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 153. CANADA NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2030 (USD MILLION)
TABLE 154. CANADA NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 155. CANADA NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 156. CANADA NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. CANADA NEUROPROTECTION MARKET SIZE, BY E COMMERCE, 2018-2030 (USD MILLION)
TABLE 158. CANADA NEUROPROTECTION MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 159. CANADA NEUROPROTECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 160. CANADA NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. CANADA NEUROPROTECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 162. CANADA NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 163. CANADA NEUROPROTECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 164. CANADA NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 165. MEXICO NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. MEXICO NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 167. MEXICO NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 168. MEXICO NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2030 (USD MILLION)
TABLE 169. MEXICO NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
TABLE 170. MEXICO NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 171. MEXICO NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 172. MEXICO NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 173. MEXICO NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 174. MEXICO NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 175. MEXICO NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 176. MEXICO NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2030 (USD MILLION)
TABLE 177. MEXICO NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 178. MEXICO NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 179. MEXICO NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. MEXICO NEUROPROTECTION MARKET SIZE, BY E COMMERCE, 2018-2030 (USD MILLION)
TABLE 181. MEXICO NEUROPROTECTION MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 182. MEXICO NEUROPROTECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 183. MEXICO NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. MEXICO NEUROPROTECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 185. MEXICO NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 186. MEXICO NEUROPROTECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 187. MEXICO NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 188. BRAZIL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. BRAZIL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 190. BRAZIL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 191. BRAZIL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2030 (USD MILLION)
TABLE 192. BRAZIL NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
TABLE 193. BRAZIL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 194. BRAZIL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 195. BRAZIL NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 196. BRAZIL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 197. BRAZIL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 198. BRAZIL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 199. BRAZIL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2030 (USD MILLION)
TABLE 200. BRAZIL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 201. BRAZIL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 202. BRAZIL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. BRAZIL NEUROPROTECTION MARKET SIZE, BY E COMMERCE, 2018-2030 (USD MILLION)
TABLE 204. BRAZIL NEUROPROTECTION MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 205. BRAZIL NEUROPROTECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 206. BRAZIL NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. BRAZIL NEUROPROTECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 208. BRAZIL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 209. BRAZIL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 210. BRAZIL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 211. ARGENTINA NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 212. ARGENTINA NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 213. ARGENTINA NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 214. ARGENTINA NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2030 (USD MILLION)
TABLE 215. ARGENTINA NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
TABLE 216. ARGENTINA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 217. ARGENTINA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 218. ARGENTINA NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 219. ARGENTINA NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 220. ARGENTINA NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 221. ARGENTINA NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 222. ARGENTINA NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2030 (USD MILLION)
TABLE 223. ARGENTINA NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 224. ARGENTINA NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 225. ARGENTINA NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. ARGENTINA NEUROPROTECTION MARKET SIZE, BY E COMMERCE, 2018-2030 (USD MILLION)
TABLE 227. ARGENTINA NEUROPROTECTION MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 228. ARGENTINA NEUROPROTECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 229. ARGENTINA NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. ARGENTINA NEUROPROTECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 231. ARGENTINA NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 232. ARGENTINA NEUROPROTECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 233. ARGENTINA NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2030 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY E COMMERCE, 2018-2030 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 258. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 260. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2030 (USD MILLION)
TABLE 262. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 264. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 266. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 268. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2030 (USD MILLION)
TABLE 270. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 272. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY E COMMERCE, 2018-2030 (USD MILLION)
TABLE 274. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 276. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 281. GERMANY NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 282. GERMANY NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 283. GERMANY NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 284. GERMANY NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2030 (USD MILLION)
TABLE 285. GERMANY NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
TABLE 286. GERMANY NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 287. GERMANY NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 288. GERMANY NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 289. GERMANY NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 290. GERMANY NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 291. GERMANY NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 292. GERMANY NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2030 (USD MILLION)
TABLE 293. GERMANY NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 294. GERMANY NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 295. GERMANY NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 296. GERMANY NEUROPROTECTION MARKET SIZE, BY E COMMERCE, 2018-2030 (USD MILLION)
TABLE 297. GERMANY NEUROPROTECTION MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 298. GERMANY NEUROPROTECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 299. GERMANY NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. GERMANY NEUROPROTECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 301. GERMANY NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 302. GERMANY NEUROPROTECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 303. GERMANY NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 304. FRANCE NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 305. FRANCE NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 306. FRANCE NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 307. FRANCE NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2030 (USD MILLION)
TABLE 308. FRANCE NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
TABLE 309. FRANCE NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 310. FRANCE NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 311. FRANCE NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 312. FRANCE NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 313. FRANCE NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 314. FRANCE NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 315. FRANCE NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2030 (USD MILLION)
TABLE 316. FRANCE NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 317. FRANCE NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 318. FRANCE NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. FRANCE NEUROPROTECTION MARKET SIZE, BY E COMMERCE, 2018-2030 (USD MILLION)
TABLE 320. FRANCE NEUROPROTECTION MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 321. FRANCE NEUROPROTECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 322. FRANCE NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 323. FRANCE NEUROPROTECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 324. FRANCE NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 325. FRANCE NEUROPROTECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 326. FRANCE NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 327. RUSSIA NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 328. RUSSIA NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 329. RUSSIA NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 330. RUSSIA NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2030 (USD MILLION)
TABLE 331. RUSSIA NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
TABLE 332. RUSSIA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 333. RUSSIA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 334. RUSSIA NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 335. RUSSIA NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 336. RUSSIA NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 337. RUSSIA NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 338. RUSSIA NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2030 (USD MILLION)
TABLE 339. RUSSIA NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 340. RUSSIA NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Neuroprotection market report include:
  • Novartis AG
  • Roche Holding AG
  • Biogen Inc.
  • Pfizer Inc.
  • AbbVie Inc.
  • Eli Lilly and Company
  • Johnson & Johnson
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • GlaxoSmithKline plc

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 336.31 Billion
Forecasted Market Value ( USD ) by 2030 $ 487.27 Billion
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Neuroprotection Therapeutics - Global Strategic Business Report - Product Image

Neuroprotection Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors Part B. International Review of Neurobiology Volume 172 - Product Image

Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors Part B. International Review of Neurobiology Volume 172

  • Book
  • Global
Mechanisms of Cell Death and Approaches to Neuroprotection/Disease Modification in Parkinson's Disease. International Review of Movement Disorders Volume 2 - Product Image

Mechanisms of Cell Death and Approaches to Neuroprotection/Disease Modification in Parkinson's Disease. International Review of Movement Disorders Volume 2

  • Book
  • Global
Indopathy for Neuroprotection: Recent Advances - Product Image

Indopathy for Neuroprotection: Recent Advances

  • Book
Hormones in Neurodegeneration, Neuroprotection, and Neurogenesis. Edition No. 1 - Product Image

Hormones in Neurodegeneration, Neuroprotection, and Neurogenesis. Edition No. 1

  • Book
  • 404 Pages

About the Neuroprotection Market

The Neuroprotection market within the context of Neurology Devices is focused on the development of products that protect the brain from damage caused by stroke, traumatic brain injury, and other neurological disorders. These products are designed to reduce the risk of long-term neurological damage and improve patient outcomes. Neuroprotection products include drugs, medical devices, and other therapies that can be used to reduce the risk of neurological damage. These products are used to reduce the risk of stroke, traumatic brain injury, and other neurological disorders. The Neuroprotection market is a rapidly growing segment of the Neurology Devices market, with a focus on improving patient outcomes and reducing the risk of long-term neurological damage. Companies in this market include Medtronic, Abbott, Boston Scientific, Stryker, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.